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A B S T R A C T
The glucagon-like peptide-1 receptor (GLP-1R) is a G-protein-coupled receptor (GPCR) and an important
target in the treatment of type 2 diabetes mellitus (T2DM). Upon stimulation with agonist, the GLP-1R
signals through both Gas and Gaq coupled pathways to stimulate insulin secretion. The agonist-induced
GLP-1R internalisation has recently been shown to be important for insulin secretion. However, the
molecular mechanisms underlying GLP-1R internalisation remain unknown. The aim of this study was to
determine the role of GLP-1R downstream signalling pathways in its internalisation. Agonist-induced
human GLP-1R (hGLP-1R) internalisation and activity were examined using a number of techniques
including immunoblotting, ELISA, immunoﬂuorescence and luciferase assays to determine cAMP
production, intracellular Ca2+ accumulation and ERK phosphorylation. Agonist-induced hGLP-1R
internalisation is dependent on caveolin-1 and dynamin. Inhibition of the Gaq pathway but not the Gas
pathway affected hGLP-1R internalisation. Consistent with this, hGLP-1R mutant T149M and small-
molecule agonists (compound 2 and compound B), which activate only the Gas pathway, failed to induce
internalisation of the receptor. Chemical inhibitors of the Gaq pathway, PKC and ERK phosphorylation
signiﬁcantly reduced agonist-induced hGLP-1R internalisation. These inhibitors also suppressed
agonist-induced ERK1/2 phosphorylation demonstrating that the phosphorylated ERK acts downstream
of the Gaq pathway in the hGLP-1R internalisation. In summary, agonist-induced hGLP-1R
internalisation is mediated by the Gaq pathway. The internalised hGLP-1R stimulates insulin secretion
from pancreatic b-cells, indicating the importance of GLP-1 internalisation for insulin secretion.
 2014 Elsevier Inc. All rights reserved.
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1. Introduction
One of the main physiological roles of glucagon-like peptide-1
(GLP-1) is to increase insulin secretion from pancreatic b-cells in a
glucose-dependent manner [1,2]. This hormone is secreted by the
intestinal L-cells after food intake [3]. GLP-1 exerts its physiologi-
cal effects by binding to its G-protein-coupled receptor (GPCR), the
GLP-1 receptor (GLP-1R). Therefore, human GLP-1R (hGLP-1R) is
an important target in the treatment of type 2 diabetes mellitus
(T2DM) [4].
Upon agonist binding, GPCRs undergo a conformational change
and transmit extracellular signals through heterotrimeric G-pro-
teins, which consist of Ga and Gbg subunits [5]. The agonist
occupied GLP-1R activates both Gas and Gaq subunits [6]. The Gas
subunit activates adenylyl cyclase (AC), increasing cyclic adeno-
sine monophosphate (cAMP) levels which in turn activate protein
kinase A (PKA) [7]. The Gaq subunit activates phospholipase
C (PLC), which in turn hydrolyses phosphatidylinositol-4,5-
bisphophate (PIP2) to inositol-1,4,5-triphosphate (IP3) and diacyl-
glycerol (DAG). IP3 binds to its receptor IP3 receptor (IP3R) on the
endoplasmic reticulum (ER), which causes cytosolic calcium (Ca2+)
accumulation [8]. DAG together with intracellular Ca2+ activates
PKC, which then induces extracellular signal-regulated kinase
(ERK) phosphorylation [9,10]. ERKs are one class of mitogen-
activated protein kinases (MAPKs) and their activity is regulated by
phosphorylation [11]. The GLP-1R has previously been shown to
activate ERK [12–15]. Further, the activation of ERK by a number of
GPCRs including the M3-muscarinic receptor has been shown to be
mediated by PKC [10,16–18]. In b-cells, the increase in intracellu-
lar Ca2+ through the Gaq pathway causes secretory vesicles
containing insulin to fuse to the plasma membrane and thereby
increases insulin exocytosis [19]. The exocytotic insulin response
caused by increased intracellular Ca2+ accumulation is potentiated
by elevated cAMP production by coupling of agonist bound GLP-1R
to the Gas pathway [20].
After activation by agonist, most GPCRs internalise from the cell
surface to dampen the biological response, to resensitise the
desensitised receptor by recycling or to propagate signals through
novel transduction pathways [21]. GPCR kinases (GRKs), arrestins
and clathrin coated pits predominantly regulate agonist-induced
GPCR internalisation. The agonist-activated GPCR is phosphory-
lated by GRKs, which facilitates the recruitment of arrestin and
targets the GPCR to clathrin-coated pits for rapid internalisation
[22]. However, some GPCRs such as endothelin A receptor (ETAR)
internalise in a caveolae-dependent manner [23]. The dynamin
family of GTPases play an important role in agonist-induced GPCR
internalisation by ﬁssion of clathrin-coated vesicles or caveolae
membranes [24]. Currently, there is some confusion whether GLP-
1R uses clathrin- or caveolin-mediated endocytosis for its agonist-
induced internalisation. It has been reported that clathrin-coated
endocytosis mediates GLP-1R internalisation and three PKC
phosphorylation sites within the C-terminal domain are important
for this to occur [25]. However, the GLP-1R has also shown to be
internalised by caveolae-mediated endocytosis [15,26]. In agonist-
stimulated pancreatic b-cells, the internalised GLP-1R colocalises
with AC within endosomes and stimulates insulin secretion
[27]. Therefore, a better understanding of GLP-1R internalisation
is essential for introducing novel agonists of the GLP-1R in the
treatment of T2DM. Although, the GLP-1R is known to activate
both Gas and Gaq coupled pathways, it is unknown as to which
pathway is required for agonist induced internalisation of GLP-1R.
In this study, it was determined that agonist-induced hGLP-1R
internalisation is caveolin-1- and dynamin-dependent. Further-
more, this study revealed that the Gaq pathway mediates agonist-
induced hGLP-1R internalisation. Consistent with this, the hGLP-
1R T149M mutant and small-molecule agonists (compounds 2 and
B) not only failed to activate the Gaq pathway, but also prevented
agonist-induced internalisation of the hGLP-1R. Additionally, the
inhibitors of Gaq signalling pathway [PBP10 (a membrane-
permeable PIP2 sequestering peptide), U73122 (a PLC inhibitor),
2-aminoethoxydiphenyl borate (2-APB, an IP3R inhibitor), BAPTA-
AM (a membrane-permeable Ca2+ chelator)], PKC (Go6976 and
Ro318820) and ERK phosphorylation (PD98059, an inhibitor for
ERK phosphorylation by MAPK) reduced agonist-induced hGLP-1R
internalisation. These inhibitors also suppressed ERK phosphor-
ylation induced by hGLP-1R activation, demonstrating that the
phosphorylated ERK acts downstream of the Gaq pathway in
hGLP-1R internalisation.
2. Materials and methods
2.1. Materials
The primary antibodies used were rabbit anti-vesicular
stomatitis virus glycoprotein (ab34774, VSVG) (Abcam Biochem-
icals, Cambridge, UK), mouse anti-green ﬂuorescent protein (GFP)
(11814460001, Roche, West Sussex, UK), mouse anti-hGLP-1R
(MAB2814, R&D Systems, Abington, UK), mouse anti-CAV-1
(sc894, Santa Cruz Biotechnology, Heidelberg, Germany), rabbit
anti-phospho ERK1/2 (9102, pERK1/2) and rabbit anti-ERK1/2
(9102, New England Biolabs, Hertfordshire, UK). The Cy3-
conjugated anti-mouse immunoglobulin G (IgG) secondary anti-
body (715-165-150, Jackson Laboratories, Suffolk, UK) was used for
immunoﬂuorescence. Horseradish peroxidase (HRP)-conjugated
anti-mouse (NA933) and anti-rabbit (NA934) IgG (GE Healthcare,
Hertfordshire, UK) secondary antibodies were used for Western
blotting. Enhanced chemiluminescence (ECL) select reagent was
obtained from GE Healthcare (Hertfordshire, UK). GLP-1 (Liraglu-
tide) was from Novo Nordisk (Sussex, UK). Compound 2 and
compound B were purchased from Calbiochem (Nottingham, UK).
Chemical inhibitors used were 2-APB, BAPTA-AM, chlorpromazine
hydrochloride, ﬁlipin complex, genistein, monodansylcadaverine
(MDC), tunicamycin (Sigma, Dorset, UK), Dynasore (Abcam
Biochemicals, Cambridge, UK), Go6976, PD98059, Ro318820,
U73122, U73343 (Tocris, Bristol, UK), PBP10 (Millipore, Notting-
ham, UK) and pentratin peptide (Thermo Scientiﬁc, Northumber-
land, UK). All other chemicals were from Sigma (Dorset, UK) unless
otherwise stated.
2.2. Plasmids
The full-length hGLP-1RDN23 cDNA was ampliﬁed from
mammalian gene collection (MGC) clone 142053 (Source Biosci-
ence, Nottingham, UK) by polymerase chain reaction (PCR) using
high-ﬁdelity Taq DNA polymerase (Roche Applied Science, West
Sussex, UK) and sequence speciﬁc primers containing EcoRI
restriction site and VSVG-tag coding sequence (50 primer), and
SalI restriction site and no stop codon (30 primer). SP-VSVG-hGLP-
1RDN23 cDNA was ampliﬁed by overlap PCR using VSVG-hGLP-
1RDN23 cDNA as the template, the sense primer, containing EcoRI
restriction site, the signal peptide (SP, 1-23aa) coding sequence
followed by VSVG coding sequence, and 30 primer. The cDNA was
digested with EcoRI and SalI, and cloned in frame into the same
sites of pEGFP-N1 vector (Clontech) for expression as the
N-terminus VSVG-tagged (after the SP) and the C-terminus GFP-
tagged fusion protein in mammalian cells. The point mutations
within the hGLP-1R were generated using Quickchange II XL
site-directed mutagenesis kit (Stratagene, Leicestershire, UK) and
SP-VSVG-hGLP-1RDN23-GFP plasmid as the template [28]. The
dominant negative (DN) mutants of dynamin K44A, b-arrestin1
D319-418 and clathrin EPS15 D95-295 used in this study have
been described previously [24,29]. The caveolae DN (CAV-1-P132L)
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was obtained from Addgene (MA, USA) [30]. The Gaq (G188S) DN
plasmid was kindly provided by Prof. Karnam S. Murthy (Virginia
Commonwealth University, USA) [31]. Luciferase pGL4.29-Luc-
CRE, pGL4.30-Luc-NFAT and pGL4.33-Luc-SRE reporter plasmids
were from Promega (Southampton, UK).
2.3. Cell culture and transfection
Human embryonic kidney 293 (HEK293) cells were maintained
at 37 8C in a 5% CO2 humidiﬁed environment in Dulbecco’s
modiﬁed Eagle medium [DMEM; serum-free medium (SFM),
Biosera, East Sussex, UK] supplemented with 10% foetal calf
serum, 2 mM glutamine, 100 U/ml penicillin and 0.1 mg/ml
streptomycin [full serum medium (FSM)]. Cells were transiently
transfected for 48 h using JetPrime transfection reagent (Polyplus;
2 ml/mg DNA, VWR, Leicestershire, UK) according to the manufac-
turer’s instructions.
2.4. ELISA
This assay is carried out as described previously with
unpermeabilised cells to quantify cell surface expression of the
receptor [24]. Brieﬂy, HEK293 cells transiently transfected with
plasmid DNA were serum starved for 1 h and then stimulated
without or with agonist at 37 8C/5% CO2. Where indicated, cells
were incubated without or with chemical inhibitors for 30 min
prior to and during stimulation with agonist at 37 8C/5% CO2. Cells
were then ﬁxed with 4% paraformaldehyde (PFA) 5 min and non-
speciﬁc binding sites blocked with 1% BSA made in TBS (1% BSA/
TBS) for 45 min. Cells were incubated with the anti-hGLP-1R
antibody (diluted 1:15,000) in 1% BSA/TBS for 1 h, washed with TBS
and then incubated with HRP-conjugated anti-mouse IgG (diluted
1:5000) in 1% BSA/TBS for 1 h. Cells were washed and developed
using 1-step Ultra TMB-ELISA substrate (Bio-Rad, Herts, UK) for
15 min and the reaction stopped by adding an equal volume of 2 M
sulphuric acid. The optical density was read at 450 nm using a plate
reader.
2.5. Immunoﬂuorescence
Intracellular localisation of hGLP-1R expression was assessed
by immunoﬂuorescence as described previously [24]. Brieﬂy, cells
were serum starved for 1 h and where indicated cells were pre-
incubated without or with inhibitors at the indicated concentra-
tion for 30 min. Cells were then incubated with the anti-hGLP-1R
mouse monoclonal antibody (diluted 1:5000) in 1% BSA/SFM for
1 h at 4 8C and then stimulated without or with agonist in the
presence of inhibitor at 37 8C/5% CO2. Cells were then ﬁxed with 4%
PFA for 30 min. Cells were permeabilised with 0.2% Triton X-100
made in PBS for 10 min, blocked in blocking buffer [1% BSA made
in wash buffer (0.1% Triton X-100 in PBS)] for 30 min and then
incubated with Cy3-conjugated anti-mouse antibody (diluted
1:200 in blocking buffer) for 1 h. Cells were then washed 3 times
with wash buffer and incubated with DAPI (D8417, 40,6-
diamidino-2-phenylindole dihydrochloride, 1 mg/ml) diluted
1:2000 in PBS to stain nucleus. Coverslips were mounted on
glass microscopic slides using mounting solution (0.1 M Tris–HCl,
pH 8.5, 10% Mowiol 50% glycerol) containing 2.5% DABCO (1,4-
diazabicyclo (2.2.2) octane). Immunoﬂuorescence staining was
visualised using a Zeiss LSM710 confocal microscope ﬁtted with a
63 oil immersion lens [28].
2.6. cAMP assay
Cells were serum starved for 1 h and then stimulated without or
with 100 nM GLP-1 for 1 h at 37 8C/5% CO2 in the presence of
0.25 mM phosphodiesterase inhibitor Ro201724. Cells were lysed
and cAMP levels in the cell lysates were assessed using the cAMP
direct immunoassay kit (Abcam, Cambridge, UK).
2.7. cAMP, Ca2+ and ERK luciferase assay
HEK293 cells cotransfected with hGLP-1R plasmid and lucifer-
ase reporter plasmid for cAMP (pGL4.29-Luc-CRE) or intracellular
Ca2+ (pGL4.30-Luc-NFAT) or ERK phosphorylation (pGL4.33-Luc-
SRE) were treated with increasing concentrations of agonist for 4 h
(cAMP and ERK) or 8 h (Ca2+) at 37 8C/5% CO2. After incubation, an
equal volume of ONE-GloTM lysis buffer containing luciferase
substrate (Promega, Southampton, UK) was added to each well and
luminescence measured using a plate reader in accordance with
the manufacturer’s instructions.
2.8. Cell lysates
To make cell lysates, HEK293 cells expressing hGLP-1R were
washed 3 times with ice-cold PBS and lysed in ice-cold modiﬁed
RIPA lysis buffer (10 mM Tris–HCl, pH 7.5, containing 10 mM EDTA,
1% NP40, 0.1% SDS, 0.5% sodium deoxycholate and 150 mM NaCl)
with 1% mammalian protease inhibitors. Cell lysates were
incubated at 4 8C for 15 min and then centrifuged at 22,000  g
for 10 min at 4 8C. The supernatant was collected and ½ volume of
3 SDS–polyacrylamide gel electrophoresis (PAGE) sample loading
buffer [75 mM Tris–HCl, pH 6.8, containing 3% SDS, 30% glycerol,
0.003% bromophenol blue and 0.3 M dithiothreitol (DTT)] was
added and left at room temperature for 1 h. These cell lysates used
to detect hGLP-1R expression by immunoblotting using the anti-
GFP and anti-VSVG antibodies.
For assessing ERK phosphorylation, HEK293 cells expressing
hGLP-1R were lysed in ice-cold modiﬁed RIPA lysis buffer (50 mM
Tris-HCl, pH 7.5, containing 0.2 M NaCl, 10 mM MgCl2, 0.1% SDS,
0.5% sodium deoxycholate, 1% TritonX-100 and 5% glycerol) with
1% mammalian protease inhibitors. Cell lysates were incubated at
4 8C for 15 min and centrifuged at 22,000  g for 10 min at 4 8C. The
supernatant was collected and ¼ volume of 5 SDS–PAGE sample
loading buffer (125 mM Tris–HCl, pH 6.8, containing 5% SDS, 50%
glycerol, 0.005% bromophenol blue and 5% b-mercaptoethanol)
was added and heated at 100 8C for 5 min. These cell lysates were
used to detect phosphorylated ERK and total ERK by immunoblot-
ting using the anti-pERK1/2 and anti-ERK1/2 antibodies.
2.9. Immunoblotting
Proteins were separated in an SDS–PAGE gel by electrophoresis
and transferred onto polyvinylidene ﬂuoride (PDVF) membrane.
Membranes were blocked with TBS-T (TBS with 0.1% Tween-20)
containing 5% milk powder (blocking buffer) for 1 h and
immunoblotted with the anti-GFP mouse antibody (diluted
1:500 in blocking buffer) to assess protein expression levels or
the anti-pERK1/2 rabbit antibody (diluted 1:1000 in blocking
buffer) to assess ERK1/2 phosphorylation for 1 h at room
temperature or overnight at 4 8C. Membranes were washed and
then incubated with the HRP-conjugated anti-mouse or anti-rabbit
secondary antibody (diluted 1:2500 in blocking buffer) for 1 h at
room temperature. Membranes were then incubated in ECL select
substrate and bands visualised using the ChemiDocTM XRS system
(Bio-Rad). Blots probed with the anti-GFP mouse antibody were
stripped with Western blot stripping buffer (Thermo Scientiﬁc)
and reprobed with the anti-VSVG rabbit antibody (diluted 1:1000)
in blocking buffer to assess protein expression levels. Blots probed
with the anti-pERK1/2 rabbit antibody were stripped and reprobed
with the anti-ERK1/2 rabbit antibody (diluted 1:1000 in blocking
buffer) to assess ERK1/2 phosphorylation [32].
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2.10. Data analysis
Data were analysed using the GraphPad Prism program. All data
are presented as means  SEM of three independent experiments.
Statistical comparisons between a control and test value was made by
a two-tailed unpaired student’s t-test. Statistical analysis between
multiple groups was determined by the Bonferroni’s post hoc test
after one-way or two-way ANOVA. A p-value <0.05 was considered
statistically signiﬁcant. Concentration response curves were also
ﬁtted using Prism, according to a standard logistic equation. Confocal
images shown in the ﬁgures are representative of 190–200
transfected cells from three different experiments. Similarly,
immunoblotting data shown in the ﬁgures are representative of
three independent experiments.
3. Results
3.1. HGLP-1R is internalised by caveolae-mediated endocytosis
The concentration (Fig. 1) and time dependency (Fig. 2) of
agonist (GLP-1)-induced internalisation of hGLP-1R was assessed
by ELISA (A) and immunoﬂuorescence (B) using HEK293 cells
transiently transfected with the receptor. The addition of 100 nM
GLP-1 to cells led to time-dependent internalisation of the hGLP-
1R with maximum internalisation observed 60 min after addition
of agonist (Fig. 2A). When added to the cells for 60 min, GLP-1
induced hGLP-1R internalisation with an EC50 of 33.65 nM and a
maximum 76% internalisation being observed at 1 mM GLP-1
(Fig. 1A). Immunoﬂuorescence staining of cells conﬁrmed the
concentration (Fig. 1B) and time dependence (Fig. 2B) of agonist-
induced internalisation of hGLP-1R, where a reduction in cell
surface expression of the receptor and an increase in intracellular
endosomal-like vesicles was observed in cells stimulated with
agonist. Furthermore, the kinetics of agonist-induced internalisa-
tion of the hGLP-1R with the N-terminal VSVG tag (after the SP)
and the C-terminal GFP tag (SP-VSVG-hGLP-1RDN23-GFP) is
identical to that of the untagged or tagged with either the
N-terminal VSVG or the C-terminal GFP hGLP-1R (data not shown).
Unless otherwise indicated, agonist treatment of 100 nM GLP-1 for
60 min was used in further experiments.
Next, the role of clathrin, caveolin and dynamin in agonist-
induced internalisation of the hGLP-1R was analysed. Most GPCRs
internalise in either a clathrin- or caveolae-dependent manner
[23,33]. Dynamin regulates both clathrin- and caveolae-mediated
endocytosis through ﬁssion of the endocytosed vesicles [34]. To
determine whether agonist-induced hGLP-1R internalisation is
mediated by clathrin or caveolae and dynamin, HEK293 cells
expressing the hGLP-1R were either cotransfected with DN
mutants (Fig. 3A) or treated with chemical inhibitors (Fig. 3B) of
clathrin, caveolae or dynamin and stimulated with agonist and
analysed by ELISA and immunoﬂuorescence. GLP-1R internalisa-
tion in the presence of chemical inhibitors or DN mutants is shown
as percentage of that in the absence of the treatment in brackets
next to the treatment.
The DN mutant of dynamin (dynamin K44A), which affects
both clathrin- and caveolae-mediated endocytosis, signiﬁcantly
reduced (33.69  3.84%, p < 0.001) agonist-induced hGLP-1R inter-
nalisation (Fig. 3A). However, clathrin DN mutants, b-arrestin1
D319-418 (89.80  6.83%, p > 0.05) and EPS15 D95-295
(86.30  5.05%, p > 0.05), had little effect on the receptors inter-
nalisation. In contrast, the DN mutant of caveolin-1 (Cav-1-P132L)
abolished hGLP-1R internalisation (0.01  0.16%, p < 0.001). Immu-
noﬂuorescence analysis conﬁrmed the inhibition of hGLP-1R
internalisation by dynamin and cavelin-1 DN mutants (Fig. 3A).
Inhibitors of clathrin-mediated endocytosis, chlorpromazine
(95.50  2.77%, p > 0.05) and MDC (94.68  3.39%, p > 0.05), had
no signiﬁcant effect on hGLP-1R internalisation. However, chemical
inhibitors of dynamin, dynasore (31.1  4.92%, p < 0.001), and
caveolae-mediated endocytosis, genistein (22.76  1.83%,
p < 0.001), and ﬁlipin (0.1  0.09%, p < 0.001) inhibited agonist-
induced hGLP-1R internalisation (Fig. 3B). These observations were
supported by immunoﬂuorescence analysis where a reduction in
agonist-induced intracellular accumulation of hGLP-1R in endo-
somes was observed in cells treated with caveolae inhibitors. These
results together demonstrate that agonist induced hGLP-1R inter-
nalisation is caveolae- and dynamin-dependent.
Fig. 1. Concentration-dependent stimulation of hGLP-1R internalisation by GLP-1. HEK293 cells expressing the hGLP-1R were stimulated with GLP-1 at the indicated
concentration for 60 min and hGLP-1R internalisation was assessed by ELISA (A) and immunoﬂuorescence (B) using the anti-hGLP-1R antibody. In immunoﬂuorescence, EGFP
(green) and the anti-hGLP-1R antibody (red) overlay is shown in yellow and nuclear staining with DAPI in blue. Data are mean  SEM, n = 3.
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Fig. 2. Time-dependent stimulation of hGLP-1R internalisation by GLP-1. HGLP-1R internalisation stimulated with 100 nM GLP-1 for the indicated time was assessed by ELISA
(A) and immunoﬂuorescence (B) using the anti-hGLP-1R antibody. In immunoﬂuorescence, EGFP (green) and the anti-hGLP-1R antibody (red) overlay is shown in yellow and
nuclear staining with DAPI in blue. Data are mean + SEM, n = 3.
Fig. 3. HGLP-1R is internalised by caveolae-mediated endocytosis. HEK293 cells expressing the hGLP-1R were either cotransfected with dominant negative mutants (A) or
treated with chemical inhibitors (B) as indicated and agonist-induced internalisation quantiﬁed by ELISA (left panel) and immunoﬂuorescence (right panel) using anti-hGLP-
1R antibody. In immunoﬂuorescence, EGFP (green) and anti-hGLP-1R antibody (red) overlay is shown in yellow and nuclear staining with DAPI in blue. Data are mean  SEM,
n = 3, n.s. p > 0.05; ***p < 0.001.
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3.2. Agonist-induced hGLP-1R internalisation is dependent on the Gaq
pathway
Upon agonist binding, the hGLP-1R acts through the Gas
coupled pathway to stimulate cAMP production and the Gaq
coupled pathway to increase intracellular Ca2+ levels [6]. However,
the involvement of these two pathways in agonist-induced hGLP-
1R internalisation is unknown. Therefore, whether agonist-
induced internalisation of the hGLP-1R was dependent on the
Gas or Gaq pathway was determined using a number of activators
and inhibitors of both the pathways (Fig. 4A). The Gas pathway
activator forskolin (99.59  0.98%, p > 0.05) and inhibitors, SQ22536
(98.43  2.9%, p > 0.05) and H89 (104.29  5.61%, p > 0.05), had no
effect on hGLP-1R agonist-induced internalisation when used at the
concentration that is optimal to induce (10 mM forskolin) or inhibit
(0.1 mM SQ22536) cAMP production or inhibit PKA activation
(10 mM H89) (Fig. 4B). In contrast, the Gaq (G188S) DN mutant
inhibited agonist-induced hGLP-1R internalisation (34  2.93%,
p < 0.001). This was further conﬁrmed by immunoﬂuorescence
(Fig. 4C). These results suggest hGLP-1R internalisation may require
the Gaq pathway.
The requirement of the Gaq pathway for agonist-induced hGLP-
1R internalisation was further assessed by using hGLP-1R T149M
mutant [35] and small-molecule agonists (compounds 2 and B) of
the hGLP-1R that are known to activate only the Gas pathway
[36–40]. The T149M mutants total protein expression (determined
by immunoblotting; Fig. 5A]), cell surface expression [assessed by
ELISA (Fig. 5B; 106.9  4.25%, p > 0.05) and immunoﬂuorescence
(Fig. 5G)]; the receptor activity [assessed by cAMP response (Fig. 5C;
107.5  0.36%, p > 0.05)] were similar to that of the hGLP-1R wild-type.
However, agonist-induced hGLP-1R internalisation was abolished by
the T149M mutation [assessed by ELISA (Fig. 5F; 1.47  0.81%,
p < 0.001) and immunoﬂuorescence (Fig. 5G)]. Moreover, intracellular
Ca2+ accumulation (Fig. 5D; 23.12  1.46%, p < 0.001) and ERK
phosphorylation (Fig. 5E; 4.14  1.5%, p < 0.001) in agonist-stimulated
cells expressing the hGLP-1R T149M mutant were signiﬁcantly
reduced. Taken together, these results suggest that the T149M
mutation of hGLP-1R affects agonist-induced internalisation of the
receptor and the activation of Gaq coupled pathway, indicating the
importance of the Gaq pathway for agonist-induced hGLP-1R
internalisation.
The small-molecule agonists, compounds 2 and B, were also
used to assess their effects on agonist-induced cAMP production
(Fig. 6A), intracellular Ca2+ accumulation (Fig. 6B), ERK
phosphorylation (Fig. 6C) and hGLP-1R internalisation [by ELISA
(Fig. 6D) and immunoﬂuorescence (Fig. 6E)]. No hGLP-1R
internalisation was observed in cells stimulated with compound
2 (0.33  0.17%, p < 0.001) or compound B (0.08  0.04%,
Fig. 4. HGLP-1R internalisation is dependent on the Gaq pathway. (A) Simpliﬁed scheme showing various inhibitors or activators of the Gas-coupled pathway or Gaq used to
assess their effect on hGLP-1R internalisation. HGLP-1R internalisation in HEK293 cells treated with the inhibitors as indicated was quantiﬁed using anti-hGLP-1R antibody
by ELISA (B) and immunoﬂuorescence (C). In immunoﬂuorescence, EGFP (green) and anti-hGLP-1R antibody (red) overlay is shown in yellow and nuclear staining with DAPI
in blue. Data are mean  SEM, n = 3, n.s. p > 0.05; ***p < 0.001.
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p < 0.001). Immunoﬂuorescence supported these observations by
demonstrating the reduction in hGLP-1R internalisation in cells
treated with small-molecule agonists, compounds 2 and B. As
observed previously by other studies [36–40], both small-molecule
agonists have induced cAMP production but not intracellular Ca2+
accumulation or ERK phosphorylation. Stimulation with optimal
concentration of compound 2 resulted in only 7.27  7.27%
(p < 0.001) intracellular Ca2+ accumulation and 20.01  8.52%
(p < 0.001) ERK phosphorylation when compared to that of GLP-1
stimulation. Compound B caused only 16.77  8.96% (p < 0.001)
intracellular Ca2+ accumulation and 13.63  7.76% (p < 0.001) ERK
phosphorylation. These results show that small-molecule agonists,
compounds 2 and B, are unable to internalise hGLP-1R or induce
intracellular Ca2+ accumulation and ERK phosphorylation, sug-
gesting that the Gaq pathway and ERK phosphorylation may be
important for agonist-induced hGLP-1R internalisation.
3.3. Inhibition of the Gaq pathway prevents agonist-induced hGLP-1R
internalisation
The Gaq pathway causes intracellular Ca
2+ accumulation by
activating PLC, which hydrolyses PIP2 to IP3 and DAG. IP3 binds to
the IP3R on the ER and increases cytosolic Ca
2+ levels. An increase in
intracellular Ca2+ levels leads to PKC activation, which then
regulates many signalling pathways including ERK phosphoryla-
tion [8,9,11]. To study the importance of the Gaq pathway in
agonist-stimulated hGLP-1R internalisation, the concentration-
dependent effect of PIP2 sequestering membrane-permeable
peptide (PBP10), PLC inhibitor (U73122), an IP3R inhibitor
(2-APB) and a membrane-permeable chelator for intracellular
calcium (BAPTA-AM) on agonist-induced hGLP-1R internalisation
was analysed (Fig. 7A–D). PBP10 inhibited internalisation of the
receptor in a concentration-dependent manner and maximal
inhibition was observed in the presence of 30 mM PBP10
(8.1  2.59%, p < 0.001). U73122 treatment also resulted in a
concentration-dependent inhibition of hGLP-1R internalisation with
maximal inhibition at 100 mM (1.93  1.84%, p < 0.001). 2-APB and
BAPTA-AM also inhibited agonist-induced hGLP-1R internalisation in
a concentration-dependent manner and resulted in maximal inhibi-
tion at 4 mM (4.81  1.21%, p < 0.001) and 1 mM (8.86  2.43%,
p < 0.001), respectively. These observations were conﬁrmed by
immunoﬂuorescence where inhibition of agonist-induced internali-
sation of hGLP-1R was evident. The negative controls, penetratin for
PBP10 (membrane-permeable peptide that does not bind PIP2),
U73343 for U73122 (inactive isomer of U73122) and BAPTA-
AM + Ca2+ for BAPTA-AM (BAPTA-AM saturated with Ca2+ is inactive
in chelating intracellular Ca2+) showed no effect on agonist-induced
hGLP-1R internalisation (data not shown). Taken together, these
results demonstrate that the Gaq pathway regulates agonist-induced
hGLP-1R internalisation.
3.4. Effect of the inhibition of PKC and ERK phosphorylation on hGLP-
1R internalisation
The accumulation of intracellular Ca2+ in the Gaq pathway
activates PKC, which has previously been shown to link the
receptors activation to ERK phosphorylation [10,16–18,41–
45]. Therefore, the effect of PKC inhibitors, Go6976 and
Ro318220, and ERK inhibitor, PD98059, on agonist-induced
internalisation of hGLP-1R was analysed (Fig. 8A–C). The PKC
Fig. 5. The T149M mutation inhibits agonist-induced hGLP-1R internalisation. HEK293 cells were transfected with hGLP-1R wild-type (WT) or T149M for 2 days. (A) Total
protein expression of WT or T149M was assessed by immunoblotting using anti-GFP and anti-VSVG antibodies. (B) HGLP-1R WT or T149M cell surface expression was
quantiﬁed by ELISA using anti-hGLP-1R antibody. HEK293 cells expressing hGLP-1R WT or T149M were stimulated with agonist and measured cAMP accumulation (C),
intracellular Ca2+ accumulation (D) and ERK phosphorylation (E) to assess hGLP-1R activity. HGLP-1R WT or T149M internalisation in HEK293 cells was assessed by ELISA (F)
and immunoﬂuorescence (G) using anti-hGLP-1R antibody. In immunoﬂuorescence, EGFP (green) and anti-hGLP-1R antibody (red) overlay is shown in yellow and nuclear
staining with DAPI in blue. Data are mean  SEM, n = 3, n.s. p > 0.05; ***p < 0.001.
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inhibitors, Go6976 and Ro318220, inhibited agonist-induced
hGLP-1R internalisation in a concentration-dependent manner,
with maximal inhibition at 100 mM (46.02  4.33%, p < 0.001 and
24.07  5.41%, p < 0.001, respectively). The ERK inhibitor PD98059
also inhibited hGLP-1R internalisation in a concentration-dependent
manner, with maximal inhibition at 100 mM (9.28  2.92%,
p < 0.001). These observations were conﬁrmed by immunoﬂuores-
cence where inhibition of agonist-induced internalisation of hGLP-1R
by these chemicals was evident. This data suggest that the agonist-
induced internalisation of the hGLP-1R is dependent on both the
activation of PKC and ERK phosphorylation.
3.5. Effect of the Gaq pathway inhibitors on GLP-1-induced ERK
phosphorylation and cAMP production
Since the activation of calcium-dependent PKC and ERK is
required for agonist-induced hGLP-1R internalisation and the
activation of Gaq pathway leads to an increase in intracellular Ca
2+
levels, we determined whether the Gaq pathway regulates
internalisation of the receptor through ERK phosphorylation. For
this purpose, the effect of inhibitors of the Gaq pathway on
agonist-induced ERK phosphorylation was assessed (Fig. 9A). The
negative controls, penetratin (for PBP10), U73343 (for U73122)
and BAPTA-AM + Ca2+ (for BAPTA-AM) showed no effect on ERK
phosphorylation (107.9  3.55, 99.63  9.93, 96  12.71%, p > 0.05,
respectively). In contrast, the PIP2 sequester, PBP10, reduced ERK
phosphorylation to 36.8  8.22% (p < 0.001). U73122, the inhibitor of
PLC, almost abolished ERK phosphorylation to 4.78  0.69%
(p < 0.001). The IP3R inhibitor, 2-APB, was also signiﬁcantly inhibited
ERK phosphorylation (46.59  8.02%, p < 0.001). Only 22.3  8.84%
(p < 0.001) ERK phosphorylation was seen in the presence of BAPTA-
AM, the chelator of intracellular Ca2+. The PKC inhibitors, Go6976 and
Ro318820, almost abolished agonist-induced ERK phosphorylation to
9.34  1.8% (p < 0.001) and 14.90  2.16% (p < 0.001) respectively.
Lastly, the MAPK inhibitor, PD98059, inhibited ERK phosphorylation
(16.03  8.1%, p < 0.001), as expected. Since the Gas pathway mediates
cAMP generation, the Gaq pathway speciﬁc inhibitors had no effect
(p > 0.05) on agonist-induced cAMP production (Fig. 9B). Taking these
results together with the effect of the inhibitors of Gaq pathway, PKC
activation and ERK phosphorylation on hGLP-1R internalisation further
indicate that the Gaq pathway regulates agonist-induced hGLP-1R
internalisation via ERK phosphorylation.
4. Discussion
Upon activation by agonist binding, many GPCRs are inter-
nalised to reduce the activity of the receptor. The internalised
GPCRs are subjected to one of two sorting fates. They are either
recycled back to the plasma membrane resulting in resensitisation
of receptors or transported to lysosomes and proteolysed leading
to long-term attenuation of signalling (down-regulation) [46]. Ag-
onist-induced GLP-1R internalisation and recycling has been
shown in transfected ﬁbroblasts and in insulinomas [47]. Currently,
it is unknown by which pathway GLP-1R internalisation occurs and
how cells respond to drugs after the initial internalisation phase.
With the possibility of drugs being produced which are adminis-
tered once a week or once a month rather than once daily. The
effects these drugs have on GLP-1R cell surface expression,
internalisation, recycling and degradation needs to be understood
for the half-life of these compounds to be prolonged further and for
the effect of ‘long-acting-release’ drugs to be successful [48]. In
pancreatic b-cells, an increase in cytosolic Ca2+ causes the release
of insulin by exocytosis [19]. The increase in intracellular Ca2+-
mediated insulin secretion is potentiated by elevated cAMP levels
Fig. 6. Small-molecule agonists activate the Gas pathway and inhibit hGLP-1R internalisation. HEK293 cells cotransfected with plasmids for hGLP-1R and the luciferase
reporter for cAMP (pGL4.29-Luc-CRE), intracellular Ca2+ (pGL4.30-Luc-NFAT) or ERK phosphorylation (pGL4.33-Luc-SRE) were stimulated with GLP-1, compound 2 and
compound B to assess cAMP generation (A), intracellular Ca2+ accumulation (B), ERK phosphorylation (C) and the receptor internalisation by ELISA (D) and
immunoﬂuorescence (E). In immunoﬂuorescence, EGFP (green) and anti-hGLP-1R antibody (red) overlay is shown in yellow and nuclear staining with DAPI in blue. Data
normalised to percentage stimulation of GLP-1 and are shown as mean  SEM, n = 3, n.s. p > 0.05; ***p < 0.001.
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Fig. 7. Effect of the Gaq pathway inhibitors on agonist-induced hGLP-1R internalisation. Agonist-induced hGLP-1R internalisation in HEK293 cells treated with various
concentrations of chemical inhibitors PBP10 (A), U73122 (B), 2-APB (C) and BAPTA-AM (D) was assessed by ELISA (left panel) and immunoﬂuorescence (right panel) using
anti-hGLP-1R antibody. In immunoﬂuorescence, EGFP (green) and anti-hGLP-1R antibody (red) overlay is shown in yellow and nuclear staining with DAPI in blue. Data are
mean  SEM, n = 3, *p < 0.05; **p < 0.01; ***p < 0.001 (# denotes the concentration used in Fig. 9).
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[20]. Upon agonist stimulation, the internalised GLP-1R has been
shown to colocalise with AC on endosomes and stimulate insulin
secretion from pancreatic b-cells demonstrating the importance of
hGLP-1R internalisation for insulin secretion [27]. Therefore,
agonist-induced internalisation of the hGLP-1R into intracellular
compartments of the cell is important for regulation of the
receptors activity [24,49]. This study systematically analysed the
involvement of the Gaq pathway in agonist-induced GLP-1R
internalisation in HEK293 model cell line.
In this study, the hGLP-1R was demonstrated, by various
approaches, to internalise by caveolae-mediated endocytosis. This
is consistent with previous ﬁndings where caveolin-1 has been
shown to interact with the hGLP-1R and other GPCRs for targeting,
internalisation and recycling of the receptor [15,23]. The GLP-1R
has been shown to activate both the Gas-coupled pathway to
generate cAMP and the Gaq-coupled pathway to cause accumula-
tion of intracellular Ca2+ [6]. In this study, inhibition of the Gaq, but
not Gas, signalling pathway markedly reduced agonist-induced
hGLP-1R internalisation, indicating a critical role for the Gaq
pathway in hGLP-1R internalisation. The serotonin 5-hydroxy-
tryptamine 2a (5-HT2A) receptor and the gonadotropin-releasing
hormone receptor (GnRHR) also couple to and internalise through
the Gaq pathway [50–53]. The T149M mutation in the hGLP-1R,
which originally identiﬁed in a T2DM patient with impaired insulin
secretion [54], has been shown to reduce agonist responsiveness
[35]. In this study, HEK293 cells expressing either hGLP-1R or its
mutant T149M demonstrated similar cAMP generation when
stimulated with GLP-1, indicating the mutation had no effect on
Fig. 8. Effect of PKC and ERK phosphorylation inhibitors on agonist-induced hGLP-1R internalisation. Agonist-induced internalisation of HGLP-1R in HEK293 cells treated with
various concentrations of PKC inhibitor Go6976 (A) or Ro318220 (B), or ERK phosphorylation inhibitor PD98059 (C) was quantiﬁed by ELISA (left panel) and
immunoﬂuorescence (right panel) using anti-hGLP-1R antibody. In immunoﬂuorescence, EGFP (green) and anti-hGLP-1R antibody (red) overlay is shown in yellow and
nuclear staining with DAPI in blue. Data are mean  SEM, n = 3, **p < 0.01; ***p < 0.001 (# denotes the concentration used in Fig. 9).
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either agonist binding to the receptor or its activity. This study also
demonstrates that the mutation, instead, signiﬁcantly reduces
agonist-induced GLP-1R internalisation by affecting intracellular
Ca2+ accumulation and ERK phosphorylation and strongly suggests
this as a possible cause for the patient’s reduced insulin secretion
found in the T2DM patient with T149M mutation [54]. Like the
T149M mutant, small-molecule agonists (compounds 2 and B)
neither activated the Gaq pathway nor induced hGLP-1R inter-
nalisation. This is consistent with previous studies that demon-
strated compounds 2 and B activate only the Gas pathway
[36–40]. Both compounds 2 and B differ from the orthosteric
agonist (GLP-1) in inducing GLP-1R internalisation and down-
stream signalling, implying ‘biased agonism’ for both small-
molecule agonists [55,56]. Further, cAMP produced in response to
hGLP-1R stimulation is important for glucose-stimulated insulin
secretion [57]. It has recently been shown that pharmacological
inhibition of GLP-1R internalisation attenuates agonist-mediated
insulin secretion [27]. This is because the internalised GLP-1R
associates with AC on endosomes to generate cAMP required for
insulin secretion. It is therefore a possibility that the T149M
mutation and small-molecule agonists (compounds 2 and B) affect
insulin secretion by inhibiting GLP-1R internalisation and thereby
endosomal cAMP generation.
In this study, chemical inhibition of PLC activation and
intracellular Ca2+ accumulation affected agonist-induced inter-
nalisation of the hGLP-1R, further demonstrating the GLP-1R
couples and internalises through the Gaq pathway [8]. Since the
increase in intracellular Ca2+ levels downstream of agonist-
stimulated GLP-1R activates PKC [8], the effect of two PKC
inhibitors, Go6976 and Ro318220, on the agonist-induced inter-
nalisation of the GLP-1R was determined. The PKC family consists
of several isoforms in humans that are activated in either a Ca2+-
dependent or independent manner. The inhibitor Go6976 is
selective for Ca2+-dependent PKC isoforms [58], whereas
Ro318220 is a broad-spectrum PKC inhibitor, which inhibits both
Ca2+-dependent and Ca2+-independent PKC isoforms [59]. The
inhibition of agonist-induced GLP-1R by both the PKC inhibitors
demonstrate the importance of Ca2+-dependent PKC isoforms for
the receptors internalisation. It is also important to note that the
GLP-1R contains three PKC phosphorylation sites within the
C-terminal domain which are important for internalisation
[25]. Removal of these phosphorylation sites has been shown to
prevent agonist-induced GLP-1R internalisation demonstrating
the importance of PKC phosphorylation of the receptor in GLP-1R
internalisation. The d-opioid receptor also requires the activation
of PKC to allow phosphorylation of the receptor for internalisation
[60]. In this study, the inhibition of PKC prevented not only
agonist-induced internalisation, but also ERK phosphorylation,
indicating that PKC may play a role in GLP-1R internalisation by
phosphorylating the receptor as well as regulating the phosphor-
ylation of ERK.
The ERK is phosphorylated by receptor tyrosine kinases in Src-
and Ras-dependent manners [9,10,61–63]. However, GPCRs
phosphorylate ERK through the Gas, Gai or Gaq pathways
depending on the receptor type and environment [64]. The ERK
phosphorylation that occurs through the Gaq pathway is highly
dependent on both intracellular Ca2+ accumulation and PKC
activation [10]. Inhibition of PKC in the a1B adrenergic receptor
[65] abolished the receptor-mediated ERK phosphorylation,
demonstrating PKC acts upstream of ERK. The results obtained
in this study strongly suggest GLP-1-mediated ERK phosphoryla-
tion occurs downstream of the PKC activation. This suggests that
the accumulation of intracellular Ca2+ and thereby activation of
Fig. 9. Effect of the Gaq pathway inhibition on agonist stimulated ERK
phosphorylation and cAMP production. HEK293 cells expressing hGLP-1R were
stimulated with agonist in the presence of Gaqpathway inhibitors and assessed ERK1/
2 phosphorylation (A) and cAMP production (B). ERK1/2 phosphorylation measured
by immunoblotting (upper panel) and quantiﬁed ERK1/2 phosphorylation by
densitometry and normalising to total ERK1/2 levels (lower panel). Data are
mean  SEM, n = 3, n.s. p > 0.05; ***p < 0.001.
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Fig. 10. Schematic representation of the pathway of agonist-induced hGLP-1R internalisation deduced from this study.
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PKC is able to induce ERK phosphorylation, linking activation of the
receptor to ERK phosphorylation. ERK phosphorylation has also
been shown to play an important role in the internalisation of
GPCRs such as the d-opioid receptor, G-CSFR and 5-HT2A receptor
[50,66–69]. Although how phosphorylated ERK regulates hGLP-1R
internalisation is unclear, it is possible that ERK phosphorylation
may regulate internalisation of the receptor through interacting
with and/or phosphorylating various signalling molecules in-
volved in agonist-induced GPCR internalisation. Consistent with
this, we have recently shown that the phosphorylated ERK1/2
regulates preadipocyte migration through dynamin [70]. It is
therefore possible that dynamin may also function downstream of
ERK in hGLP-1R internalisation.
In conclusion, these results demonstrate that caveolin-1 plays
an important role in hGLP-1R trafﬁcking to the cell surface and its
internalisation in HEK293 cells. Upon agonist activation, the hGLP-
1R signals through the Gaq pathway to hydrolyse PIP2 by PLC to
generate IP3. IP3 binds the IP3R and increases cytosolic Ca
2+
accumulation, which then leads to the activation of PKC. In turn,
this leads to the phosphorylation of ERK via the MAPK pathway
[8]. In this study, the inhibitors of the Gaq pathway, PKC activation
and ERK phosphorylation affected not only hGLP-1R internalisa-
tion but also ERK phosphorylation, indicating that together they
play a vital role in agonist-induced internalisation of the receptor
(Fig. 10). In this study, the hGLP-1R T149M mutation, which was
previously found in Japanese patient with T2DM and impaired
insulin secretion, and small-molecule agonists (compounds 2 and
B), of GLP-1R also inhibited agonist-induced hGLP-1R internalisa-
tion. This suggests an important role for hGLP-1R internalisation in
insulin secretion.
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